Clostridium Difficile Infection (CDI) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026

Clostridium Difficile Infection Emerging Therapy and TPP Insights

Thelansis’s “Clostridium Difficile Infection (CDI) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Clostridium Difficile Infection Overview

Clostridioides difficile (formerly Clostridium difficile) infection (CDI) is caused by a spore-forming anaerobic bacterium that produces toxins A and B. It often follows antibiotic exposure, which disrupts gut microbiota and allows bacterial overgrowth. Symptoms include watery diarrhoea, abdominal pain and fever; severe cases may cause colitis, pseudomembranes, toxic megacolon or sepsis. Diagnosis combines compatible symptoms with stool testing, since asymptomatic carriage can yield positive results. Fidaxomicin is preferred for initial and recurrent episodes when available; oral vancomycin remains an alternative. Persistent spores and microbiota disruption contribute to recurrence. For adults with recurrent CDI, FDA-approved Rebyota and Vowst restore microbiota to reduce recurrence after antibacterial therapy; neither treats active infection. Investigational strategies include microbiome therapies and toxin-targeting antibodies, with AZD5148 in a Phase IIb recurrence-prevention trial.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs

*Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
  • Pipeline analysis
  • Target patients for emerging therapies
  • Key companies
  • Key mechanism of actions
  • Launch date estimates, etc.
• Clinical trial landscape analysis
  • Target patient segments
  • Trial endpoints
  • Trial design
  • Recruitment criteria, etc.
• Unmet Needs and Opportunities
  • Performance of key current therapies
  • Top areas of unmet needs
  • Opportunity sizing for key unmet needs
• Target Product Profiles
  • Attributes and levels
  • Physician likelihood of prescribing
  • Expected patient shares
• KOL insights on key emerging therapies
  • Level of awareness
  • Expected use / line of therapy
  • Extent to fulfil key unmet needs
  • KOL quotes

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.

2. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key emerging therapies – profiles and KOL insights

3. Product Attribute Analysis

• Key takeaways
• Scientific attributes
• Commercial attributes
• Product positioning

4. Primary Market Research

• Current treatment landscape
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Current challenges
  • Unmet needs
• Emerging therapies
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Unmet needs and KOL expectations

5. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

6. Regulatory and Reimbursement Environments (by country and payer insights)

7. Appendix (e.g., bibliography, methodology)